"Overall survival rate" trang 1 - tải miễn phí từ tailieuXANH
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
5    51    0
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors
10    63    0
Nomogram to predict overall survival based on the log odds of positive lymph nodes for patients with endometrial carcinosarcoma after surgery

Nomogram to predict overall survival based on the log odds of positive lymph nodes for patients with endometrial carcinosarcoma after surgery
11    239    1
Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: A single-arm, phase 2 study

Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: A single-arm, phase 2 study
8    17    1
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
8    253    1
Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib

Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib
7    85    0
Treatment results of locally advanced cervical cancer by external beam radiotherapy and low dose rate brachytherapy at Hue Central Hospital

Treatment results of locally advanced cervical cancer by external beam radiotherapy and low dose rate brachytherapy at Hue Central Hospital
7    52    0
Overall survival and prognostic factors prostate cancer in Kurdistan Province-Iran: A population-based study (2011-2018)

Overall survival and prognostic factors prostate cancer in Kurdistan Province-Iran: A population-based study (2011-2018)
10    227    2
Both comorbidity and worse performance status are associated with poorer overall survival after external beam radiotherapy for prostate cancer

Both comorbidity and worse performance status are associated with poorer overall survival after external beam radiotherapy for prostate cancer
8    31    0
Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy

Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy
6    70    0
A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
7    66    0
Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: A real-world chart review study

Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: A real-world chart review study
11    96    1
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2- negative metastatic breast cancer: A network meta-analysis

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2- negative metastatic breast cancer: A network meta-analysis
17    89    0
Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma

Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma
8    87    0
Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma

Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma
8    71    0
A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer

A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer
8    50    0
AMAFRICA, a patient-navigator program for accompanying lymphoma patients during chemotherapy in Ivory Coast: A prospective randomized study

AMAFRICA, a patient-navigator program for accompanying lymphoma patients during chemotherapy in Ivory Coast: A prospective randomized study
8    70    0
Expression of HIF-1α and VEGF in feline mammary gland carcinomas: Association with pathological characteristics and clinical outcomes

Expression of HIF-1α and VEGF in feline mammary gland carcinomas: Association with pathological characteristics and clinical outcomes
10    15    1
Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: A single-center retrospective study

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: A single-center retrospective study
9    163    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.